Michael Thomas Henderson, Chief Executive Officer at Apogee Therapeutics, Inc. (APGE), sold 20,000 shares at $82.05 ($1.6M) on 2026-05-13, disclosed to the SEC on 2026-05-15.
Scheduled sale ($1.6M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $82.05 | 18,659 | $1.5M | 93.3% |
| 2 | $82.58 | 1,341 | $111K | 6.7% |
| Total | $82.09 avg | 20,000 | $1.6M | 100% |
| Filing → |
| SYRE | SELL | 2026-06-23 | $2.0M | — | Filing → |
| APGE | SELL | 2026-06-12 | $1.7M | — | Filing → |
| SYRE | SELL | 2026-05-08 | $6.0M | — | Filing → |